AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30638154 — intervention group
Group type: COMPARATOR
Intervention: High-intensity resistance circuit-based training in normoxia (HRCnorm)
Number of subjects: 28
Study 30638154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HRChyp and HRCnorm
Number of subjects: 28
Study 29529231 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progressive feeding
Number of subjects: 60
Study 29529231 — intervention group
Group type: COMPARATOR
Intervention: Delayed progressive feeding (control)
Number of subjects: 60
Study 26895326 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical free vascularized lymph node transfer (LNT) followed by 6 months of physiotherapy and compression
Number of subjects: 36
Study 26895326 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy and compression alone for 6 months
Number of subjects: 36
Study 25296066 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 284
Study 25296066 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 284
Study 22901359 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0249 5-10 mg/d
Number of subjects: 72
Study 22901359 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate 54-72 mg/d
Number of subjects: 72
Study 22901359 — intervention group
Group type: COMPARATOR
Intervention: MK-0249
Number of subjects: 72
Study 22901359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20077576 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain exercises
Number of subjects: 27
Study 20077576 — intervention group
Group type: COMPARATOR
Intervention: Closed kinetic chain exercises
Number of subjects: 27
Study 20077576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (open and closed kinetic chain exercises)
Number of subjects: 27
Study 20077576 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 27
Study 17084625 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% DHEA cream applied twice daily
Number of subjects: 75
Study 17084625 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily
Number of subjects: 75
Study 16270721 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast plus budesonide
Number of subjects: 20
Study 16270721 — intervention group
Group type: COMPARATOR
Intervention: Formoterol plus budesonide
Number of subjects: 20
Study 11801579 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome (3 or 5 mg/kg/day)
Number of subjects: 0
Study 11801579 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome
Number of subjects: 0
Study 11801579 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study 12579713 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy (group 1)
Number of subjects: 120
Study 12579713 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy (group 2)
Number of subjects: 120
Study 12579713 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with scleral flaps tightly sutured with releasable sutures (group 3)
Number of subjects: 120
Study 8801243 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinterview suggestion about depression
Number of subjects: 52
Study 2228983 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified multiple monitored ECT (MMECT) limited to two seizure inductions in a session
Number of subjects: 29
Study 2228983 — intervention group
Group type: COMPARATOR
Intervention: Conventional electroconvulsive therapy (ECT)
Number of subjects: 29
Study 2228983 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified multiple monitored ECT (MMECT)
Number of subjects: 29
Study 528125 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine resin 30 mg for eight weeks followed by placebo for eight weeks (Group 1)
Number of subjects: 80
Study 528125 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo for eight weeks followed by phentermine for eight weeks (Group 2)
Number of subjects: 80
Study 528125 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks (Group 3)
Number of subjects: 80
Study 528125 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo for eight weeks followed by phentermine for eight weeks (Group 4)
Number of subjects: 80
Study 528125 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine for 'slow losers'
Number of subjects: 80
Study 528125 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 'slow losers'
Number of subjects: 80
Study 31437006 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patients (vSPs)
Number of subjects: 60
Study 31437006 — intervention group
Group type: COMPARATOR
Intervention: Real Standardized Patients (rSPs)
Number of subjects: 60
Study 30744605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled PCR testing of dried blood spots (DBS)
Number of subjects: 1170
Study 30744605 — intervention group
Group type: COMPARATOR
Intervention: Individual patient testing
Number of subjects: 1170
Study 30744605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled PCR testing
Number of subjects: 1170
Study 28874970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged physiotherapy and rehabilitation for 6 months
Number of subjects: 60
Study 28874970 — intervention group
Group type: COMPARATOR
Intervention: Early surgical discectomy
Number of subjects: 60
Study 26467327 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 121
Study 26467327 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 121
Study 23536720 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMAb, OA5D5v2) administered i.v. once every three weeks in combination with erlotinib
Number of subjects: 137
Study 23536720 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in combination with erlotinib
Number of subjects: 137
Study 21790275 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized e-mail newsletter
Number of subjects: 109
Study 21790275 — intervention group
Group type: COMPARATOR
Intervention: Generic e-mail newsletter
Number of subjects: 109
Study 19645607 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 19
Study 15879360 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.55 g ethanol/kg body weight)
Number of subjects: 8
Study 15879360 — intervention group
Group type: COMPARATOR
Intervention: Drinking-water
Number of subjects: 8
Study 12903918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cleansing with an electric toothbrush and povidone-iodine solution before surgery, followed by rinsing twice a day after surgery
Number of subjects: 32
Study 12903918 — intervention group
Group type: COMPARATOR
Intervention: Systemic cephazolin administration (3 g x day(-1) for 5 days) without oral cleansing
Number of subjects: 32
Study 10566428 — intervention group
Group type: EXPERIMENTAL
Intervention: Touchscreen information systems
Number of subjects: 345
Study 8759983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular fosphenytoin equimolar to oral phenytoin dose
Number of subjects: 240
Study 8759983 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 240
Study 8759983 — intervention group
Group type: COMPARATOR
Intervention: Oral phenytoin
Number of subjects: 240
Study 2032595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem colonoscopy
Number of subjects: 63
Study 7125336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naloxone (0.8 mg)
Number of subjects: 10
Study 7125336 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naloxone (10 mg)
Number of subjects: 10
Study 7125336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31000896 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) infusion
Number of subjects: 66
Study 31000896 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium sulphate)
Number of subjects: 66
Study 29110848 — intervention group
Group type: EXPERIMENTAL
Intervention: One nodule
Number of subjects: 3392
Study 29110848 — intervention group
Group type: EXPERIMENTAL
Intervention: Two nodules
Number of subjects: 3392
Study 29110848 — intervention group
Group type: EXPERIMENTAL
Intervention: Three nodules
Number of subjects: 3392
Study 29110848 — intervention group
Group type: EXPERIMENTAL
Intervention: Four nodules
Number of subjects: 3392
Study 29110848 — intervention group
Group type: EXPERIMENTAL
Intervention: >4 nodules
Number of subjects: 3392
Study 25511549 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 48
Study 25511549 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 48
Study 22517542 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain 3000 FIP units
Number of subjects: 0
Study 22517542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21640839 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI; selective serotonergic reuptake inhibitor)
Number of subjects: 40
Study 21640839 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (SNRI; selective noradrenergic reuptake inhibitor)
Number of subjects: 40
Study 21640839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18303229 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiniti vision system
Number of subjects: 39
Study 18303229 — intervention group
Group type: COMPARATOR
Intervention: Series 20,000 Legacy system
Number of subjects: 39
Study 17167299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical intervention and sixteen 90-minute supervised exercise sessions over 8 weeks (n=126)
Number of subjects: 251
Study 17167299 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=125)
Number of subjects: 251
Study 15569338 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban regimen A: 250-microg/kg bolus, with an additional 250-microg/kg bolus allowed
Number of subjects: 13
Study 15569338 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban regimen B: 250-microg/kg bolus followed by 2-microg/kg/min infusion
Number of subjects: 13
Study 15569338 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban regimen C: steady-state, 2-microg/kg/min infusion initiated 4 hours before dialysis
Number of subjects: 13
Study 15569338 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens (A, B, C)
Number of subjects: 13
Study 11426017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose d-penicillamine
Number of subjects: 134
Study 11426017 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose d-penicillamine
Number of subjects: 134
Study 11426017 — intervention group
Group type: COMPARATOR
Intervention: Previous controlled SSc trials (control group)
Number of subjects: 134
Study 9298518 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (800 mg/day)
Number of subjects: 191
Study 9298518 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 191
Study 7961554 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment (initial 6-week trial)
Number of subjects: 29
Study 7961554 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment (continued treatment)
Number of subjects: 29
Study 7961554 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment with plasma concentrations above 350 ng/mL
Number of subjects: 29
Study 3498747 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (specific drugs include indomethacin and naproxen)
Number of subjects: 444
Study 3498747 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (specifically indomethacin, 150 mg/day)
Number of subjects: 444
Study 3498747 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (in control group)
Number of subjects: 444
Study 30545531 — intervention group
Group type: EXPERIMENTAL
Intervention: Novafen
Number of subjects: 168
Study 30545531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 168
Study 27463942 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 17322
Study 27463942 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 17322
Study 25043068 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery ablation (thoracoscopy group, n = 66)
Number of subjects: 138
Study 25043068 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (catheter group, n = 72)
Number of subjects: 138
Study 25043068 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery ablation (thoracoscopy group)
Number of subjects: 138
Study 25043068 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (catheter group)
Number of subjects: 138
Study 22824225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic randomized controlled trial design
Number of subjects: 0
Study 20409284 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and Health Education (W/HE) programme
Number of subjects: 557
Study 20409284 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 557
Study 18424099 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 1280 mg daily for 12 weeks
Number of subjects: 75
Study 18424099 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 75
Study 18424099 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE)
Number of subjects: 75
Study 16604429 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-session drug prevention program in 7th through 9th grades
Number of subjects: 2042
Study 16604429 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-session drug prevention program in 7th through 9th grades (60% or more participation)
Number of subjects: 2042
Study 14971524 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa 250 mg twice daily
Number of subjects: 40
Study 14971524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10890661 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric insufflation
Number of subjects: 50
Study 10890661 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard insertion technique)
Number of subjects: 50
Study 8940228 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 42
Study 8940228 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 42
Study 1405378 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with increased Kt/V (urea) (initial Kt/V (urea) 0.82 +/- 0.19; final Kt/V (urea) 1.32 +/- 0.21)
Number of subjects: 30
Study 1405378 — intervention group
Group type: COMPARATOR
Intervention: Control group with unchanged Kt/V (urea) (initial Kt/V (urea) 0.82 +/- 0.16; final Kt/V (urea) 0.87 +/- 0.15)
Number of subjects: 30
Study 2876744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g sulphasalazine daily for six months
Number of subjects: 60
Study 2876744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28234714 — intervention group
Group type: EXPERIMENTAL
Intervention: SIC session with HPMS
Number of subjects: 14
Study 28234714 — intervention group
Group type: COMPARATOR
Intervention: SIC session without HPMS
Number of subjects: 14
Study 28234714 — intervention group
Group type: COMPARATOR
Intervention: Control session with HPMS ingestion only
Number of subjects: 14
Study 27307573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimpanzee adenovirus 63 and modified vaccinia virus Ankara-vectored vaccine expressing a multiepitope string fused to TRAP and 3 doses of RTS,S/AS01B (group 1; n=20)
Number of subjects: 37
Study 27307573 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of RTS,S/AS01B alone (group 2; n=17)
Number of subjects: 37
Study 27307573 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated; n=6)
Number of subjects: 37
Study 27307573 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat CHMI after 6 months (group 1)
Number of subjects: 37
Study 27307573 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat CHMI after 6 months (group 2)
Number of subjects: 37
Study 23102675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B-TURP)
Number of subjects: 295
Study 23102675 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M-TURP)
Number of subjects: 295
Study 21953739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phonics-based intervention program for reading difficulties, tailored to Swedish orthography, one-to-one tutoring for twelve weeks
Number of subjects: 112
Study 21953739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phonics-based intervention program for reading difficulties
Number of subjects: 112
Study 19391032 — intervention group
Group type: EXPERIMENTAL
Intervention: JuicePlus + (nutritional product composed primarily of dehydrated juice concentrates from mixed fruits and vegetables) for 28 days
Number of subjects: 92
Study 19391032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19391032 — intervention group
Group type: EXPERIMENTAL
Intervention: JuicePlus + (nutritional product)
Number of subjects: 92
Study 17710003 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine every 6, 12, or 24 hours plus methylprednisolone every 4 to 5 days
Number of subjects: 160
Study 17710003 — intervention group
Group type: COMPARATOR
Intervention: Single injection of bupivacaine and methylprednisolone at intervals of 4 to 5 days
Number of subjects: 160
Study 15601521 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL-P300
Number of subjects: 0
Study 15601521 — intervention group
Group type: EXPERIMENTAL
Intervention: AMTL-N400
Number of subjects: 0
Study 11496850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir plus efavirenz
Number of subjects: 195
Study 11496850 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 195
Study 11496850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 195
Study 11496850 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy (nelfinavir plus efavirenz and two nucleoside analogues)
Number of subjects: 195
Study 11496850 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with efavirenz
Number of subjects: 195
Study 11496850 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy
Number of subjects: 195
Study 9919013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeline HCl (intravenous injections in incremental doses)
Number of subjects: 15
Study 8116700 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (300 micrograms/min for 2 hours)
Number of subjects: 120
Study 8116700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8116700 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 120
Study 8116700 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban and Placebo
Number of subjects: 120
Study 3056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 3056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 3056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 3056445 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (added to primary drug)
Number of subjects: 0
Study 31769395 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive case detection (RACD) system
Number of subjects: 40
Study 31769395 — intervention group
Group type: COMPARATOR
Intervention: Private health facilities (HF)
Number of subjects: 40
Study 30928650 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 605
Study 28347835 — intervention group
Group type: EXPERIMENTAL
Intervention: >40% reduced standardized activity level (SAL)
Number of subjects: 1008
Study 28347835 — intervention group
Group type: EXPERIMENTAL
Intervention: >40% reduced SAL (after adjustment for clinical covariates)
Number of subjects: 1008
Study 28347835 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline in SAL following a nonfatal VTA and HFE
Number of subjects: 1008
Study 24297379 — intervention group
Group type: EXPERIMENTAL
Intervention: SrRan 2 g/day
Number of subjects: 330
Study 24297379 — intervention group
Group type: EXPERIMENTAL
Intervention: SrRan 1 g/day
Number of subjects: 330
Study 24297379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 24660579 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (50 sessions)
Number of subjects: 288
Study 24660579 — intervention group
Group type: COMPARATOR
Intervention: Seretide (salmeterol 50 µg/fluticasone 250 µg, twice a day)
Number of subjects: 288
Study 22134677 — intervention group
Group type: EXPERIMENTAL
Intervention: Childcare discount of $8.92 per session attended
Number of subjects: 174
Study 22134677 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive (control group)
Number of subjects: 174
Study 22134677 — intervention group
Group type: EXPERIMENTAL
Intervention: Childcare discount
Number of subjects: 174
Study 22134677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost simulations
Number of subjects: 174
Study 19841119 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 180
Study 19841119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral formula feeding
Number of subjects: 180
Study 19841119 — intervention group
Group type: COMPARATOR
Intervention: Control (no pain relief intervention)
Number of subjects: 180
Study 22835927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 217
Study 22835927 — intervention group
Group type: COMPARATOR
Intervention: Control (no adenoidectomy)
Number of subjects: 217
Study 15768570 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT)
Number of subjects: 230
Study 15768570 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Intervention (GMI)
Number of subjects: 230
Study 12444940 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 120 mg (subsequently 60 mg) once daily
Number of subjects: 301
Study 12444940 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 301